Esperion Therapeutics, Inc. $ESPR Stock Holdings Lifted by Invesco Ltd.

Invesco Ltd. raised its stake in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 161.1% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 255,480 shares of the biopharmaceutical company’s stock after buying an additional 157,647 shares during the period. Invesco Ltd. owned 0.13% of Esperion Therapeutics worth $368,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Synergy Asset Management LLC increased its stake in shares of Esperion Therapeutics by 3,496.3% in the first quarter. Synergy Asset Management LLC now owns 31,000 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 30,138 shares during the period. Private Advisor Group LLC increased its stake in shares of Esperion Therapeutics by 33.2% in the first quarter. Private Advisor Group LLC now owns 40,106 shares of the biopharmaceutical company’s stock worth $58,000 after purchasing an additional 10,000 shares during the period. Crestline Management LP bought a new position in shares of Esperion Therapeutics in the fourth quarter worth about $63,000. SLT Holdings LLC increased its stake in shares of Esperion Therapeutics by 66.7% in the first quarter. SLT Holdings LLC now owns 50,000 shares of the biopharmaceutical company’s stock worth $72,000 after purchasing an additional 20,000 shares during the period. Finally, Foundations Investment Advisors LLC increased its stake in shares of Esperion Therapeutics by 66.3% in the first quarter. Foundations Investment Advisors LLC now owns 50,172 shares of the biopharmaceutical company’s stock worth $72,000 after purchasing an additional 20,000 shares during the period. 47.39% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

ESPR has been the topic of a number of recent research reports. HC Wainwright reissued a “buy” rating and set a $16.00 target price on shares of Esperion Therapeutics in a research report on Tuesday, June 17th. Wall Street Zen downgraded Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, August 25th. Four research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, Esperion Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $7.00.

Esperion Therapeutics Trading Up 5.9%

NASDAQ ESPR opened at $2.68 on Friday. The stock’s 50 day moving average is $1.67 and its two-hundred day moving average is $1.36. The company has a market capitalization of $540.34 million, a price-to-earnings ratio of -5.47, a PEG ratio of 60.20 and a beta of 0.89. Esperion Therapeutics, Inc. has a 1-year low of $0.69 and a 1-year high of $3.94.

Esperion Therapeutics (NASDAQ:ESPR) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.15. Esperion Therapeutics had a negative return on equity of 0.91% and a negative net margin of 35.84%.The business had revenue of $82.39 million for the quarter, compared to the consensus estimate of $62.55 million. On average, analysts predict that Esperion Therapeutics, Inc. will post -0.29 earnings per share for the current year.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.